Merck & Co, INC Form 4 insider transactions

Johannes Oosthuizen, President, U.S. Market at Merck & Co., Inc., sold 8,500 shares of common stock at an average price of $84.0876 on February 19, 2025.

Executive Vice President and Chief Information & Digital Officer of Merck & Co., David Michael Williams, reports the sale of 6,000 shares of common stock on February 13, 2025.

Johannes Oosthuizen, a Merck executive, reports the vesting and distribution of restricted stock units and subsequent stock transactions.

Director Inge G. Thulin acquired additional shares of Merck & Co. common stock on February 6, 2025.

Cristal N. Downing, Chief Communications & Public Affairs Officer at Merck & Co., Inc., reported the sale of 2,361 shares of common stock on February 6, 2025.

Director Douglas M. Baker Jr. of Merck & Co., Inc. reports the acquisition and disposal of common stock on February 5, 2025.

Jennifer Zachary, EVP and General Counsel of Merck & Co., Inc., reports the acquisition of 25,423 shares of common stock and disposal of shares following the satisfaction of performance criteria for performance share units.

David Michael Williams, EVP, Chief Info & Digital Officer at Merck & Co., Inc., acquired 10,246 shares of common stock following the satisfaction of performance criteria for performance share units.

Dalton Smart, SVP Fin. Global Controller at Merck & Co., Inc., reports acquiring 2,586 shares of common stock at $97.94 per share following the satisfaction of performance criteria for performance share units.

Johannes Oosthuizen, President, U.S. Market at Merck & Co., Inc., reports acquiring 8,664 shares of common stock following the satisfaction of performance criteria for performance share units.

Caroline Litchfield, EVP & CFO of Merck & Co., Inc., acquired 23,432 shares of common stock on January 27, 2025, following the satisfaction of performance criteria for performance share units.

Executive VP & President, MRL, Dean Y. Li, reports acquisition and disposal of Merck & Co., Inc. common stock following the satisfaction of performance criteria for performance share units.

Cristal N. Downing, Chief Communications & Public Affairs Officer at Merck & Co., Inc., acquired 9,446 shares of common stock on January 27, 2025, following the satisfaction of performance criteria for performance share units.

Richard R. DeLuca, EVP & President of Merck Animal Health, reports acquisition and disposal of Merck & Co., Inc. common stock.

Merck's CEO, Robert M. Davis, acquired 95,275 shares of common stock on January 27, 2025, following the satisfaction of performance criteria for performance share units granted in 2022.

Executive Vice President of Merck & Co., Sanat Chattopadhyay, reports acquiring shares of common stock following the satisfaction of performance criteria for performance share units.

Chief Marketing Officer of Merck & Co., Chirfi Guindo, reports acquisition and disposal of common stock and adjustments in 401(k) holdings.

Merck & Co. director Christine E. Seidman acquired phantom stock units equivalent to 81.6747 shares of common stock on December 31, 2024.

Director Thomas H. Glocer of Merck & Co., Inc. reported the disposition of 5,100 common stock shares and the acquisition of 490.0483 phantom stock units.

Mary Ellen Coe, a director at Merck & Co., Inc., reported the acquisition of phantom stock units settled in cash, according to a Form 4 filing with the SEC.

A Merck & Co. director, Surendralal L. Karsanbhai, acquired phantom stock units equivalent to 552.8749 shares of common stock.

Christine E. Seidman, a director at Merck & Co., Inc., reported the acquisition of phantom stock units and holdings in common stock through dividend reinvestment.

Director Thomas Glocer reports a transaction involving Merck & Co., Inc. stock, including the acquisition of phantom stock units.

Director Mary Ellen Coe reports acquisition of phantom stock units convertible to common stock in a recent SEC filing.

Chief Marketing Officer Chirfi Guindo of Merck & Co., Inc. reports the acquisition and disposal of company stock and restricted stock units.

Christine E. Seidman, a director at Merck & Co., Inc., acquired phantom stock units on June 28, 2024, according to a Form 4 filing with the SEC.

Director Thomas H. Glocer reports the acquisition of phantom stock units in Merck & Co., Inc., settled in cash upon termination of service.

Mary Ellen Coe, a director at Merck & Co., reported the acquisition of phantom stock units settled in cash, according to a recent SEC Form 4 filing.

Patricia F. Russo, a director at Merck & Co., Inc., reported changes in her beneficial ownership of the company's stock, including the acquisition of phantom stock units.

Christine E. Seidman, a director at Merck & Co., Inc., reported the acquisition of phantom stock units settled in cash, along with other holdings including shares acquired in dividend reinvestment transactions.